Clinical Trial: A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807995) titled 'A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy' on Aug. 20.

Brief Summary: The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

Study Start Date: Sept. 18

Study Type: INTERVENTIONAL

Condition: Immunoglobulin A Nephropathy

Intervention: DRUG: Povetacicept

Subcutaneous injection administration.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Vertex Pharmaceuticals Incorporated

Published by HT Digital Content Services with permission from Health Daily Di...